METTL3 and autoimmune disease: Li H.B. et al. (2017) found that m6A modification controlled T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. After the knockout of METTL3, m6A modification in T cells decreased, thus impairing their ability to differentiate. Consequently, these T cells could not cause autoimmune diseases, providing a new way to alleviate autoimmune diseases with drugs that target m6A modification (Li H.B. et al., 2017).